Showing results (591-600 of 1,508) with videos related to

Sort By:
Pageof 151
Current Atherosclerosis Reports|September 28, 2023
Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?Benjamin N Wadström, Anders B Wulff, Kasper M Pedersen, et al.
Atherosclerosis|May 7, 2026
Inflammation may explain part of atherosclerotic cardiovascular disease risk conferred by elevated remnant lipoproteins: a cohort and Mendelian randomization studyBenjamin N Wadström, Anders B Wulff, Kasper M Pedersen, et al.
Rhinology|July 20, 2020
Predominance of an altered sense of smell or taste among long-lasting symptoms in patients with mildly symptomatic COVID-19P Boscolo-Rizzo, J Polesel, G Spinato, et al.
Hormones and Behavior|December 8, 2004
Elevated urinary testosterone excretion and decreased maternal caregiving effort in marmosets when conception occurs during the period of infant dependenceJeffrey E Fite, Jeffrey A French, Kimberly J Patera, et al.
Protein Science : a Publication of the Protein Society|January 1, 1997
Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpinsW S Chang, J Whisstock, P C Hopkins, et al.
Biochemistry|March 29, 1994
Electric field and conformational effects of cytochrome c and solvent on cytochrome c peroxidase studied by high-resolution fluorescence spectroscopyH Anni, J M Vanderkooi, K A Sharp, et al.
International Clinical Psychopharmacology|March 16, 2021
Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trialLenard A Adler, Robert Goldman, Seth C Hopkins, et al.
The New England Journal of Medicine|April 16, 2020
A Non-D2-Receptor-Binding Drug for the Treatment of SchizophreniaKenneth S Koblan, Justine Kent, Seth C Hopkins, et al.
Clinical Drug Investigation|November 25, 2015
Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in AdultsSeth C Hopkins, Soujanya Sunkaraneni, Estela Skende, et al.
Clinical Pharmacology and Therapeutics|May 7, 2021
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood DisordersSeth C Hopkins, Scott Wilkinson, Taryn J Corriveau, et al.
Pageof 151